BridgeBio Pharma Inc. (BBIO)

NASDAQ: BBIO · Real-Time Price · USD

37.93

-0.43 (-1.12%)

At close: May 01, 2025, 11:53 AM

-1.12% (1D)

Bid	37.89
Market Cap	7.2B
Revenue (ttm)	127.42M
Net Income (ttm)	-667.97M
EPS (ttm)	-3.56
PE Ratio (ttm)	-10.65
Forward PE	-14.26
Analyst	Buy

Ask	37.93
Volume	2,057,014
Avg. Volume (20D)	3,120,111
Open	38.25
Previous Close	38.36
Day's Range	36.85 - 38.48
52-Week Range	21.62 - 39.54
Beta	1.08

About BBIO

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-car...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 27, 2019

Employees 725

Stock Exchange NASDAQ

Ticker Symbol BBIO

Website https://www.bridgebio.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is $50, which is an increase of 31.82% from the latest price.

Stock Forecasts

Earnings Surprise

BridgeBio Pharma has released their quartely earnings on Apr 29, 2025:

Revenue of $116.6M exceeds estimates by $58.88M, with -44.77% YoY decline.

EPS of -0.88 exceeds estimates by 0.12, with -340.00% YoY decline.

Why Price Moved

1 day ago New

+5.33%

BridgeBio Pharma shares are trading higher after t... Unlock content with Pro Subscription

17 hours ago New

+1.48%

BridgeBio Pharma shares are trading higher after the company reported better-than-expected Q1 financial results.

News

1 day ago · seekingalpha.com

BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript

BridgeBio Pharma, Inc. (NASDAQ:BBIO ) Q1 2025 Earnings Conference Call April 29, 2025 4:30 PM ET Company Participants Chinmay Shukla – Vice President-Strategic Finance Neil Kumar – Chief Executive Off...

1 day ago · zacks.com

BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.05 per share a year ago.

1 week ago · seekingalpha.com

BridgeBio: Early Signs Point To Blockbuster Revenues

BridgeBio Pharma's Attruby shows strong potential in treating ATTR-CM, with a 42% reduction in mortality, competitive pricing, and convenient pill form. Early commercial launch success, high conversio...

1 month ago · benzinga.com

Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s BBIO acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardio...

1 month ago · fool.com

Prediction: BridgeBio Pharma Will Beat the Market. Here's Why

Explore the exciting world of BridgeBio Pharma (BBIO -5.42%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and...

2 months ago · seekingalpha.com

BridgeBio: Strong Start For Attruby

Attruby is off to a strong start in the United States, with more than 1,000 unique prescriptions in less than three months since FDA approval. I now see more patients on Attruby by year-end than I ant...

2 months ago · zacks.com

BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates

BridgeBio Pharma (BBIO) came out with a quarterly loss of $1.31 per share versus the Zacks Consensus Estimate of a loss of $1.09. This compares to loss of $0.96 per share a year ago.